Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial
Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial
复制标题
DOI：
10.1016/j.jcf.2012.07.006
复制
发表时间：
2013-03-01
影响因子：
5.2
通讯作者：
Oermann, Christopher M.
中科院分区：
文献类型：
--
作者：
Assael, Baroukh M.;Pressler, Tacjana;Oermann, Christopher M.
背景：比较氨曲南雾化吸入溶液(AZLI)和妥布霉素钠溶液(TNS)治疗囊性纤维化合并铜绿假单胞菌的国际试验。方法：273例患者，随机分为3个28天疗程(Azli 75 mg[3次/d]或TNS 300 mg[2次/d])；每个疗程28个休息日。结果：268例患者接受治疗(Azli/TNS：136/132)。平均基线FEV1预测值为52%。1个疗程后平均相对变化(Azli：8.35%；TNS：0.55%；p
Background: Open-label, parallel-group, international trial comparing aztreonam for inhalation solution (AZLI) and tobramycin nebufizer solution (TNS) for cystic fibrosis patients with airway Pseudomonas aeruginosa.Methods: 273 patients (>= 6 years); randomized to three 28-day courses (AZLI 75 mg [three-times/day] or TNS 300 mg [twice/day]); 28 off-days separated each course.Results: 268 patients were treated (AZLI/TNS: 136/132). Mean baseline FEV1 was 52% predicted. Mean relative changes after 1 course (AZLI: 8.35%; TNS: 0.55%; p